JP2022529824A5 - - Google Patents

Info

Publication number
JP2022529824A5
JP2022529824A5 JP2021562908A JP2021562908A JP2022529824A5 JP 2022529824 A5 JP2022529824 A5 JP 2022529824A5 JP 2021562908 A JP2021562908 A JP 2021562908A JP 2021562908 A JP2021562908 A JP 2021562908A JP 2022529824 A5 JP2022529824 A5 JP 2022529824A5
Authority
JP
Japan
Prior art keywords
seq
txnrd1
pharmaceutical composition
inhibitor
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021562908A
Other languages
English (en)
Japanese (ja)
Other versions
JP7770924B2 (ja
JP2022529824A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029513 external-priority patent/WO2020219668A1/en
Publication of JP2022529824A publication Critical patent/JP2022529824A/ja
Publication of JP2022529824A5 publication Critical patent/JP2022529824A5/ja
Priority to JP2025081069A priority Critical patent/JP2025127483A/ja
Application granted granted Critical
Publication of JP7770924B2 publication Critical patent/JP7770924B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021562908A 2019-04-24 2020-04-23 Ｒａｓ変異体癌を治療するための組成物および方法 Active JP7770924B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025081069A JP2025127483A (ja) 2019-04-24 2025-05-14 Ｒａｓ変異体癌を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838065P 2019-04-24 2019-04-24
US62/838,065 2019-04-24
PCT/US2020/029513 WO2020219668A1 (en) 2019-04-24 2020-04-23 Compositions and methods for treating ras-mutant cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025081069A Division JP2025127483A (ja) 2019-04-24 2025-05-14 Ｒａｓ変異体癌を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022529824A JP2022529824A (ja) 2022-06-24
JP2022529824A5 true JP2022529824A5 (https=) 2023-05-01
JP7770924B2 JP7770924B2 (ja) 2025-11-17

Family

ID=72941253

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562908A Active JP7770924B2 (ja) 2019-04-24 2020-04-23 Ｒａｓ変異体癌を治療するための組成物および方法
JP2025081069A Pending JP2025127483A (ja) 2019-04-24 2025-05-14 Ｒａｓ変異体癌を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025081069A Pending JP2025127483A (ja) 2019-04-24 2025-05-14 Ｒａｓ変異体癌を治療するための組成物および方法

Country Status (5)

Country Link
US (1) US20220193109A1 (https=)
EP (1) EP3959199A4 (https=)
JP (2) JP7770924B2 (https=)
CN (1) CN114025772A (https=)
WO (1) WO2020219668A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3054109T3 (en) 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
CN113952359A (zh) * 2021-11-19 2022-01-21 大连理工大学盘锦产业技术研究院 顺铂与Tri-1的联合抗肺癌药物组合物及其应用
EP4551214A1 (fr) * 2022-07-05 2025-05-14 Association Française contre les Myopathies Utilisation de l'ebselen ou l'un de ses derives pour traiter des pathologies ou dysfonctionnements des mitochondries

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5697297B2 (ja) * 2004-05-14 2015-04-08 ロゼッタ ジノミクス リミテッド マイクロｎａｓおよびその使用
US20090312373A1 (en) * 2008-03-11 2009-12-17 The General Hospital Corporation Methods for the treatment of cancer using piperlongumine and piperlongumine analogs
EP2954328A1 (en) * 2013-02-05 2015-12-16 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
KR20150131312A (ko) * 2013-03-15 2015-11-24 미르나 테라퓨틱스 인코포레이티드 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료
WO2016040657A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
CN106659705A (zh) * 2014-09-10 2017-05-10 加利福尼亚大学董事会 通过prostratin靶向k‑ras介导的信号转导通路和恶性肿瘤
GB201514021D0 (en) * 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
WO2018145090A1 (en) * 2017-02-06 2018-08-09 New York University Methods of treating cancers having a deregulated nrf2/keap1 pathway
AU2018273356B2 (en) * 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3630089A4 (en) * 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. PROCEDURE FOR CANCER THERAPY
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法

Similar Documents

Publication Publication Date Title
US10238649B2 (en) Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
US20210260059A1 (en) Mdm2 inhibitors and combinations thereof
JP2022529824A5 (https=)
US12275986B2 (en) Biomarkers associated with checkpoint immune therapy and methods of using same
JP2020514311A (ja) がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ
JP2014505658A (ja) 癌を治療する方法
AU2021382148A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
AU2021227007A1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
TW202302112A (zh) 索托拉西布給藥方案
KR20250100726A (ko) 암 치료에 있어서 아제노세르팁에 대한 간헐적 투여 요법
CN115776889A (zh) 用于治疗非小细胞肺癌的egfr tki
JP2019530711A5 (https=)
CN110840892A (zh) 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途
TW202042810A (zh) 一種含cdk4/6抑制劑的組合物與阿那曲唑聯合在製備治療腫瘤疾病的藥物中的用途
CN119604291A (zh) Blu-945联合奥斯替尼治疗非小细胞肺癌
KR20240004589A (ko) 소토라십 제형
JP2013513614A (ja) 膵臓癌を処置する方法
US20200316067A1 (en) Combination of raf inhibitors and taxanes
TW202200147A (zh) Ｂｅｌｖａｒａｆｅｎｉｂ用於癌症治療
TW202131922A (zh) 用於治療癌症的表皮生長因子受體酪胺酸激酶抑制劑
CN106999485B (zh) 抗肺鳞癌的喹啉衍生物
Urbini et al. 2017P Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
HK40105136A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
HK40105135A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
Deng et al. Tyrosine Kinase Inhibitors in the Elderly: A Case Report and Literature Review on Toxicity Profiles